Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
A patient with PNH and persistent anemia during ravulizumab therapy experienced improved hemoglobin after danicopan was added, while an extended infusion delay highlighted treatment-continuity challenges without establishing protection from interrupted C5 inhibition.
Hematology September 24th 2026
Pharmacy Practice News
New consensus guidance favors once-daily oral iron and simplified IV administration, including fewer test doses, premedications, and infusion visits. Several recommendations depart from established protocols and require formulation-specific clinical judgment.
Gastroenterology September 8th 2026
Cureus
Two long-term proton pump inhibitor users presented with severe macrocytic anemia, markedly elevated LDH, and low haptoglobin suggestive of hemolysis. Further evaluation identified combined vitamin B12 and folate deficiency, highlighting a diagnostic mimic of true hemolytic anemia.
Family Medicine/General Practice August 17th 2026
The 2026 KDIGO anemia in CKD guideline replaces two long-standing iron deficiency classifications, endorses proactive high-dose IV iron in maintenance hemodialysis, and provides first-ever positioning guidance on HIF-PHIs, 14 years after the previous version.
Clinical Pharmacology May 29th 2026
Hematology Advisor
“Extreme endurance exercise pushes red blood cells toward accelerated aging through mechanisms that mirror what we observe during blood storage.” — Angelo D’Alessandro, PhD, University of Colorado Anschutz
Cardiology March 17th 2026
First-line treatment with IV iron dextran is the cost-effective strategy for managing IDA in women with HMB at commonly accepted willingness-to-pay thresholds.
Hematology February 2nd 2026